Schott Pharma, a drug containment and delivery systems specialist, has committed to taking responsibility for the reduction of its emissions, with the goal of limiting global warming to 1.5 °C.
The independent Science Based Targets initiative (SBTi) has validated the company's climate action plan, which will focus on energy efficiency, green electricity and advancements in technology to reduce greenhouse gas emissions.
“The time to act on climate change is now. We must all take responsibility – governments, society and companies. At SCHOTT Pharma, it’s our priority to drive solutions for a more sustainable future. In particular, we are focusing on decarbonisation through various initiatives ranging from green electricity use to low-emission manufacturing technology, ecodesign and circular economy,” said CFO of SCHOTT Pharma, Dr Almuth Steinkühler.
The company is basing its decarbonisation efforts off the Paris Agreement, which is a global initiative to improve the sustainability of energy use and reduce emissions to ensure a better future.
Schott Pharma's sustainability targets include:
- Reducing Scope 1 and Scope 2 GHG emissions by 46.2% by 2030
- Reducing 27.5% of Scope 3 GHG emissions related to fuel and energy-related activities (Scope 3.3) and its investments (Scope 3.15) by 2030
- The company's supply chain to source 74.23% of purchased goods and services (Scope 3.1), capital goods (Scope 3.2) and upstream transport and distribution (Scope 3.4) from suppliers with their own science-based target commitments by 2027.
As per guidance of SBTi on Organizational Boundary, the target validation process was executed at the parent- or group level rather than for SCHOTT Pharma alone.
